Medical cannabis producer, supplier and exporter Althea Group Holdings
(ASX:AGH) has seen a record month for patient uptake in September.
Althea CEO Josh Fegan says “[w]e are very pleased to have exceeded our estimates with regard to patient uptake in Australia.
In June we achieved our 1,000 patient milestones almost six months ahead of schedule and less than three months later we have reached 2,329 patients.” This comes as we see softening of the regulations for prescribers of medicinal cannabis in NSW.
From 30 September 2019, in most cases only a Therapeutic Goods Administration issued approval will be required.
Shares in Althea Group Holdings
(ASX:AGH) trading 8.1 per cent higher at 67 cents.
